News headlines about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.868422019134 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s analysis:

Several brokerages recently commented on MRNS. ValuEngine lowered Marinus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, July 7th. JMP Securities restated an “outperform” rating and set a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday.

Shares of Marinus Pharmaceuticals (MRNS) remained flat at $3.81 during midday trading on Wednesday. 1,276,518 shares of the stock traded hands. The firm’s 50 day moving average is $2.58 and its 200 day moving average is $1.70. Marinus Pharmaceuticals has a 12-month low of $0.82 and a 12-month high of $5.44. The company’s market capitalization is $99.35 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. On average, equities research analysts expect that Marinus Pharmaceuticals will post ($0.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Marinus Pharmaceuticals (MRNS) Share Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-marinus-pharmaceuticals-mrns-share-price.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Insider Buying and Selling by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.